



STELARA, JAMTEKI, STEQEYMA, WEZLANA (ustekinumab)

### Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

# Part A - Patient Patient Information

Patient information	<u>//                                   </u>				
First Name:			Last Name:		
Insurance Carrier N	lame/Number:		<del>,</del>		
Group Number:		Client ID:			
Date of Birth (YYYY/MM/DD):		Relationship: Employee Spouse Dependent			
Language: English French			Gender: Male Female		
Address:					
City:		Province:		Postal Code:	
Email address:					
Telephone (home):		Telephone (cell):		Telephone (work):	
_	ox that applies to the pat		University or College for	ull-time). A copy of the enrolment document	
	in over-age student depe tional institution confirm			un-time). A copy of the emolinem document	
The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.					
Coordination of be	enefits				
Provincial Coverage		You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.			
Primary Coverage	Has the patient applied What is the coverage d		nder a primary plan?	Yes No N/A	





STELARA, JAMTEKI, STEQEYMA, WEZLANA (ustekinumab)

### **Authorization**

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





STELARA, JAMTEKI, STEQEYMA, WEZLANA (ustekinumab)

### Part B - Prescriber

**SECTION 1 - DRUG REQUESTED** 

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

☐ STELARA	☐ JAMTE	KI 🗌	STEQEYMA		1	New request
					F	Renewal request*
DIN(s)	Dose	Administration (ex: ora	al, IV, etc)	Frequency	/	Duration
Site of drug administrat					_	
Home Phys	ician's office/Private	Clinic Private Clin	c (within Hos	spital - no publ	ic or gov	vernment funding)
Hospital (inpatient)	Hospital (out	patient)				
Name of the hospital or	private clinic:					
Address:						
City:	I e	rovince:		Postal cod	10.	
City.	[	TOVITICE.		Fostar coc	ic.	
* Please submit proof	of prior coverage if a	/ailable				
SECTION 2 – ELIGIBI	ILITY CRITERIA					
1. Please indicate if the	he patient satisfies the	e below criteria:				
Psoriatic Arthritis						
	ent of psoriatic arthrit	is in an adult, AND				
	•	response or has a docume	nted intolera	nce to at least	2 disea	ase modifying anti-
rheumatic drugs (DMARDs), or to another biologic response modifier						
Diamen Bassiants						
Plaque Psoriasis	ant of madarata to acc	vovo ploguo poorigojo ANI				
For the treatment of moderate to severe plaque psoriasis, AND						
The patient is 6 years of age or older, AND  The patient has an affected body surface area (PSA) of 10% or greater, or there is involvement of the patient's face.						
The patient has an affected body surface area (BSA) of 10% or greater, or there is involvement of the patient's face, hands, feet or genital region, AND						
The patient has a Psoriasis Area and Severity Index (PASI) score of 10 or greater, AND						
The patient has had an inadequate response or has a documented intolerance to phototherapy, unless it is inaccessible, AND						
The patient has had an inadequate response or has a documented intolerance to conventional systemic therapy, or to another biologic response modifier						





STELARA, JAMTEKI, STEQEYMA, WEZLANA (ustekinumab)

Crohn's Disease						
For the treatment of moderately to severely active Crohr	's disease in an adult, AND					
The patient has had an inadequate response or has a d immunomodulators, or corticosteroids, AND	The patient has had an inadequate response or has a documented intolerance to either aminosalicylates, immunomodulators, or corticosteroids, AND					
The patient has had an inadequate response or has a d factor (TNF) inhibitor (e.g. adalimumab, infliximab)	The patient has had an inadequate response or has a documented intolerance to at least one tumour necrosis factor (TNF) inhibitor (e.g. adalimumab, infliximab)					
Ulcerative Colitis						
For the treatment of moderately to severely active ulcer	ative colitis in an adult, AND					
The patient has had an inadequate response or has a documented intolerance to corticosteroids and to either aminosalicylates or immunomodulators						
OR						
None of the above criteria applies.						
Relevant additional information:						
2. Additional criteria for STELARA requests						
The patient is intolerant to, or had a confirmed adverse	event with a biosimilar					
SECTION 3 – PRESCRIBER INFORMATION						
Physician's Name:						
Address:						
Tel:	Fax:					
License No.:	Specialty:					
Physician Signature:	Date:					





STELARA, JAMTEKI, STEQEYMA, WEZLANA (ustekinumab)

#### SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at <a href="https://www.sunlife.ca/privacy">www.sunlife.ca/privacy</a> or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET

CEV.	TION	_	CONIT	ΓΑСΤΙ	ΙIC
JEU	HUH	ິ –	CUIN	ACI	υJ

You can submit **all** pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.

**OR** 

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept.
PO Box 2010 STN Waterloo
Waterloo, ON N2J 0A6